Results 261 to 270 of about 50,635 (295)

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas [PDF]

Acta Neuropathologica, 2018
According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO), IDH-mutant astrocytic gliomas comprised WHO grade II diffuse astrocytoma, IDH-mutant (AII), WHO grade III anaplastic astrocytoma, IDH ...
Felix Sahm, Christian Koelsche, Kristin Huang   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The source of IDH-mutant gliomas

Science
Deep sequencing of human brain tissue identifies the probable cell of origin of IDH-mutant ...
Christopher W, Mount, Mario L, Suvà
openaire   +2 more sources

[Glioblastoma, IDH-Wildtype].

No shinkei geka. Neurological surgery, 2023
The 5th edition of the WHO Classification of Central Nervous System Tumours(WHO2021)emphasizes the importance of molecular classification. A significant update was that glioblastoma IDH-mutant from WHO2016 was renamed and classified as astrocytoma IDH-mutant WHO grade 4 in WHO2021.
Ichiyo, Shibahara, Toshihiro, Kumabe
openaire   +1 more source

Glioblastoma, IDH-wildtype

Abstract The 2021 World Health Organization (WHO) classification defines glioblastoma as a malignant tumor of neuroglial or astroglial origin that lacks mutations in the isocitrate dehydrogenase (IDH) 1 or 2 genes. The new definition of glioblastoma also includes IDH-wildtype tumors without histological features of WHO grade 4 if one of ...
Michael Weller, E. Antonio Chiocca, Sabine Mueller, Jennifer S. Yu, Andreas von Deimling   +4 more
  +4 more sources

IDH Inhibition

Clinical Lymphoma Myeloma and Leukemia, 2020
openaire   +2 more sources

IDH-Inhibitoren

Der Onkologe, 2017
Alwin Krämer, Michael Heuser
openaire   +1 more source

De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma

Cancer Cell, 2022
Stefan Gradl
exaly  

The implications of IDH mutations for cancer development and therapy

Nature Reviews Clinical Oncology, 2021
Christopher J Pirozzi, Hai Yan, Pirozzi Christopher J   +2 more
exaly  

IDH Inhibitors for the Treatment of IDH-Mutated Cancer

2019
Lenny Dang, Brandon Nicolay, Zenon Konteatis   +2 more
openaire   +1 more source

IDH Snippets

2017
P. Anandan, Vidya Natampally, Srinivasa Ranganathan   +2 more
openaire   +1 more source